JP2020532285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532285A5 JP2020532285A5 JP2020500686A JP2020500686A JP2020532285A5 JP 2020532285 A5 JP2020532285 A5 JP 2020532285A5 JP 2020500686 A JP2020500686 A JP 2020500686A JP 2020500686 A JP2020500686 A JP 2020500686A JP 2020532285 A5 JP2020532285 A5 JP 2020532285A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- fusion protein
- polypeptide
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023085796A JP2023120208A (ja) | 2017-07-11 | 2023-05-24 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
| JP2025044077A JP2025118590A (ja) | 2017-07-11 | 2025-03-18 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531215P | 2017-07-11 | 2017-07-11 | |
| US62/531,215 | 2017-07-11 | ||
| PCT/US2018/041661 WO2019014360A1 (en) | 2017-07-11 | 2018-07-11 | POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023085796A Division JP2023120208A (ja) | 2017-07-11 | 2023-05-24 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532285A JP2020532285A (ja) | 2020-11-12 |
| JP2020532285A5 true JP2020532285A5 (cg-RX-API-DMAC7.html) | 2021-11-25 |
| JP7684803B2 JP7684803B2 (ja) | 2025-05-28 |
Family
ID=63036501
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500686A Active JP7684803B2 (ja) | 2017-07-11 | 2018-07-11 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
| JP2023085796A Pending JP2023120208A (ja) | 2017-07-11 | 2023-05-24 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
| JP2025044077A Pending JP2025118590A (ja) | 2017-07-11 | 2025-03-18 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023085796A Pending JP2023120208A (ja) | 2017-07-11 | 2023-05-24 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
| JP2025044077A Pending JP2025118590A (ja) | 2017-07-11 | 2025-03-18 | 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11498960B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3625265A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7684803B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20250099285A (cg-RX-API-DMAC7.html) |
| CN (3) | CN117327188A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2018301412B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019028269A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3067247A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2020000369A2 (cg-RX-API-DMAC7.html) |
| IL (3) | IL271920B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2024005945A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019014360A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL271920B2 (en) | 2017-07-11 | 2024-03-01 | Alexion Pharma Inc | Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof |
| US20210388070A1 (en) * | 2018-10-30 | 2021-12-16 | Alexion Pharmaceuticals, Inc. | Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions |
| EP3956344A1 (en) * | 2019-04-16 | 2022-02-23 | University of Washington | Amantadine binding protein |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| US12447173B2 (en) | 2019-12-26 | 2025-10-21 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition containing double-stranded ribonucleic acid inhibiting expression of complement C5 |
| JP7343618B2 (ja) | 2020-01-17 | 2023-09-12 | オリンパス株式会社 | 発光装置、および駆動装置 |
| US20230416344A1 (en) | 2020-04-16 | 2023-12-28 | Alexion Pharmaceuticals, Inc. | Methods for treating a complement mediated disorder caused by viruses |
| US20230357442A1 (en) * | 2020-10-05 | 2023-11-09 | Alexion Pharmaceuticals, Inc. | Methods of treating dermatomyositis |
| TW202417490A (zh) * | 2022-08-31 | 2024-05-01 | 美商艾力克森製藥公司 | 用於治療鐮狀細胞病的融合多肽之劑量及投與 |
| CN116731149B (zh) * | 2023-06-07 | 2024-02-27 | 华中农业大学 | 草鱼补体活化分子碳末端肽C5a-CP及应用 |
| CN119241699B (zh) * | 2024-09-24 | 2025-11-28 | 广州康盛生物科技股份有限公司 | 一种抗人补体c5的单域抗体及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
| CN1203178C (zh) | 1997-10-27 | 2005-05-25 | 尤尼利弗公司 | 多价抗原结合蛋白 |
| CA2921260A1 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| EP1355919B1 (en) * | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| AU2003286002B2 (en) * | 2002-11-08 | 2011-06-16 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| CA2512545C (en) | 2003-01-10 | 2015-06-30 | Karen Silence | Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf) |
| AU2012254935B2 (en) * | 2004-02-12 | 2014-05-29 | Archemix Llc | Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders |
| JP2008500830A (ja) * | 2004-06-01 | 2008-01-17 | ドマンティス リミテッド | 増加した血清半減期を有する二重特異性融合抗体 |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| CN100368022C (zh) | 2005-09-20 | 2008-02-13 | 中国人民解放军第二军医大学 | 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法 |
| KR101030612B1 (ko) * | 2005-10-21 | 2011-04-20 | 에프. 호프만-라 로슈 아게 | 폴리펩타이드의 재조합 발현 방법 |
| NZ567483A (en) | 2005-11-04 | 2012-04-27 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| US8435512B2 (en) | 2008-03-03 | 2013-05-07 | Novelmed Therapeutics, Inc. | Anti-properdin antibodies |
| HUE026179T2 (en) * | 2008-08-05 | 2016-05-30 | Novartis Ag | Preparations and methods for antibodies against complement C5 protein |
| CN102597005A (zh) | 2009-06-23 | 2012-07-18 | 阿雷克森制药公司 | 与补体蛋白质结合的双特异性抗体 |
| EP3009455A1 (en) | 2009-09-16 | 2016-04-20 | Immunomedics Inc. | Class i anti-cea antibodies and uses thereof |
| EP2507262A1 (en) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| EP2531523A1 (en) * | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| CN103003302B (zh) | 2010-03-10 | 2015-09-30 | 诺沃姆德治疗公司 | 人源化和嵌合抗-备解素抗体 |
| TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| CN110437320B (zh) | 2010-07-09 | 2023-10-20 | 阿菲博迪公司 | 多肽 |
| TW201241008A (en) | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| AU2012279288B2 (en) | 2011-07-01 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Anti-properdin antibodies and uses thereof |
| CA2859493A1 (en) | 2011-12-21 | 2013-06-27 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| CN104114187A (zh) | 2011-12-28 | 2014-10-22 | 诺沃姆德治疗公司 | 去糖基化的人类抗体、其融合蛋白质及用途 |
| EP4616914A3 (en) | 2012-02-20 | 2025-11-19 | IPC Research, LLC | Polypeptides binding to human complement c5 |
| JP2015532303A (ja) | 2012-10-04 | 2015-11-09 | ノベルメド セラピューティクス，インコーポレーテッド | 溶血性疾患を治療するための補体第２経路特異的抗体 |
| KR20160068744A (ko) | 2013-08-28 | 2016-06-15 | 애피바디 에이비 | 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드 |
| KR102446636B1 (ko) | 2013-08-28 | 2022-09-23 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 인간 보체 c5에 결합하는 안정한 폴리펩티드 |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| WO2018140956A1 (en) | 2017-01-30 | 2018-08-02 | Alexion Pharmaceuticals, Inc. | Monovalent anti-properdin antibodies and antibody fragments |
| IL271920B2 (en) | 2017-07-11 | 2024-03-01 | Alexion Pharma Inc | Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof |
-
2018
- 2018-07-11 IL IL271920A patent/IL271920B2/en unknown
- 2018-07-11 AU AU2018301412A patent/AU2018301412B2/en active Active
- 2018-07-11 KR KR1020257021037A patent/KR20250099285A/ko active Pending
- 2018-07-11 CN CN202311281139.3A patent/CN117327188A/zh active Pending
- 2018-07-11 CN CN201880046102.3A patent/CN111201246B/zh active Active
- 2018-07-11 BR BR112019028269-6A patent/BR112019028269A2/pt unknown
- 2018-07-11 JP JP2020500686A patent/JP7684803B2/ja active Active
- 2018-07-11 KR KR1020207002889A patent/KR102806328B1/ko active Active
- 2018-07-11 EP EP18746529.9A patent/EP3625265A1/en active Pending
- 2018-07-11 CN CN202311281093.5A patent/CN117327187A/zh active Pending
- 2018-07-11 US US16/629,687 patent/US11498960B2/en active Active
- 2018-07-11 CA CA3067247A patent/CA3067247A1/en active Pending
- 2018-07-11 WO PCT/US2018/041661 patent/WO2019014360A1/en not_active Ceased
- 2018-07-11 KR KR1020257014994A patent/KR20250068795A/ko active Pending
-
2020
- 2020-01-08 MX MX2024005945A patent/MX2024005945A/es unknown
- 2020-01-08 MX MX2024005946A patent/MX2024005946A/es unknown
- 2020-01-15 CO CONC2020/0000369A patent/CO2020000369A2/es unknown
-
2022
- 2022-10-07 US US17/938,756 patent/US12221473B2/en active Active
-
2023
- 2023-05-24 JP JP2023085796A patent/JP2023120208A/ja active Pending
- 2023-09-21 IL IL307197A patent/IL307197B1/en unknown
-
2025
- 2025-01-02 US US19/007,782 patent/US20250163138A1/en active Pending
- 2025-01-16 AU AU2025200303A patent/AU2025200303A1/en active Pending
- 2025-01-16 AU AU2025200313A patent/AU2025200313A1/en active Pending
- 2025-03-18 JP JP2025044077A patent/JP2025118590A/ja active Pending
- 2025-10-21 IL IL324119A patent/IL324119A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532285A5 (cg-RX-API-DMAC7.html) | ||
| JP2023120208A5 (cg-RX-API-DMAC7.html) | ||
| JP2024063213A5 (cg-RX-API-DMAC7.html) | ||
| AU2016351710B2 (en) | Improved serum albumin-binding immunoglobulin variable domains | |
| DK2443137T3 (en) | NOVEL chemokine-binding peptides capable of impeding the sequence for immunity, inflammation and cancer | |
| EP2847229B1 (en) | Single domain binding molecule | |
| CN110835371A (zh) | 抗ccr8单克隆抗体及其应用 | |
| JP2020501550A5 (cg-RX-API-DMAC7.html) | ||
| WO2018233574A1 (zh) | 一种抗pd-l1人源化纳米抗体及其应用 | |
| RU2015141418A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| JP2016053091A5 (cg-RX-API-DMAC7.html) | ||
| CN113966343A (zh) | 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法 | |
| JP2016508143A5 (cg-RX-API-DMAC7.html) | ||
| CN101378781B (zh) | 制造免疫球蛋白的组合物和方法 | |
| JP2020535811A5 (cg-RX-API-DMAC7.html) | ||
| CN112390884B (zh) | Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用 | |
| CN114591432B (zh) | 抗TNFα的单域抗体及其用途 | |
| US20240117053A1 (en) | Clec12a antibody fragment sequences and methods | |
| CN117860786B (zh) | 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途 | |
| CN117843777B (zh) | 用于炎性疾病治疗的新型纳米抗体及其产品和方法 | |
| WO2022011717A1 (zh) | 针对新型冠状病毒的纳米抗体及其应用 | |
| JPH0213376A (ja) | 緑膿菌に対するモノクローナル抗体、ならびにその調製および使用 | |
| RU2020102910A (ru) | Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния | |
| CN108295242A (zh) | 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用 | |
| CN116390954A (zh) | 靶向bcma的单域抗体 |